» Articles » PMID: 30707500

Design, Synthesis, and Evaluation of Lipopeptide Conjugates of Mercaptoundecahydrododecaborate for Boron Neutron Capture Therapy

Overview
Journal ChemMedChem
Specialties Chemistry
Pharmacology
Date 2019 Feb 2
PMID 30707500
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

We developed new B carriers for boron neutron capture therapy (BNCT) that can effectively transport and accumulate boron clusters into cells. These carriers consist of a lipopeptide, mercaptoundecahydrododecaborate (BSH), and a disulfide linker. The carriers were conceived according to the structure of pepducin, a membrane-penetrating lipopeptide targeting protease-activated receptor 1 (PAR1). To improve the membrane permeability of BSH, the structure was optimized using various lipopeptides possessing different peptides and lipid moieties. These synthesized lipopeptides were conjugated with BSH and evaluated for intracellular uptake using T98G glioblastoma cells. Among them, the most effectively incorporated and accumulated in the cells was compound 5 a, which contains a peptide of 13 residues derived from the intracellular third loop of PAR1 and a palmitoyl group. For further improvement of B accumulation in cells, the introduction of an amine linker was investigated; intracellular uptake similar to that of 5 a was observed for compound 14, which has a piperazine linker. Both compounds 5 a and 14 showed a stronger radiosensitizing effect than BSH along on T98G cells under mixed-neutron beam irradiation. The results demonstrate that lipopeptide conjugation is effective for enhancing intracellular delivery and accumulation of BSH and improving the cytotoxic effect of BNCT.

Citing Articles

Current Insights into the Radiobiology of Boron Neutron Capture Therapy and the Potential for Further Improving Biological Effectiveness.

Punshon L, Fabbrizi M, Phoenix B, Green S, Parsons J Cells. 2025; 13(24.

PMID: 39768156 PMC: 11674336. DOI: 10.3390/cells13242065.


Current research trends and hotspots of boron neutron capture therapy: a bibliometric and visualization analysis.

Cong Y, Abulimiti M, Matsumoto Y, Jin J Front Oncol. 2024; 14:1507157.

PMID: 39726703 PMC: 11669655. DOI: 10.3389/fonc.2024.1507157.


Peptide Conjugated Boron Neutron Capture Therapy for Enhanced Tumor Targeting.

Jyothi V, Kommineni N Nanotheranostics. 2024; 8(4):458-472.

PMID: 38961887 PMC: 11217788. DOI: 10.7150/ntno.95251.


Proposal of recommended experimental protocols for in vitro and in vivo evaluation methods of boron agents for neutron capture therapy.

Hattori Y, Andoh T, Kawabata S, Hu N, Michiue H, Nakamura H J Radiat Res. 2023; 64(6):859-869.

PMID: 37717596 PMC: 10665309. DOI: 10.1093/jrr/rrad064.


Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry.

Flieger S, Takagaki M, Kondo N, Lutz Jr M, Gupta Y, Ueda H Int J Mol Sci. 2023; 24(8).

PMID: 37108137 PMC: 10139035. DOI: 10.3390/ijms24086973.